Luminary Therapeutics, Inc.
Minneapolis, MN
- UEI
- MNKBAEZHWJS1
- CAGE
- 8D9M3
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Other NAICS codes in SAM.gov
- SAM.gov registration date
- Physical address
- 1200 S Washington Ave #260, Minneapolis, MN 55415, USA
- Website
- luminarytx.com
- Founded
- 2019
- Employees
- 1-10
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
About the company
Luminary Therapeutics, Inc. is a corporate entity registered in SAM.gov since August 2, 2019, specializing in advanced cellular immunotherapy research focused on developing innovative cancer and autoimmune disease treatments. As a self-certified small disadvantaged business and for-profit organization, the company concentrates on developing cutting-edge chimeric antigen receptor (CAR) T-cell therapies that target complex medical challenges across various disease states. The company's research primarily involves engineering sophisticated T-cell therapies that can potentially revolutionize treatment approaches for solid tumors and autoimmune conditions.
Through federal grant awards from agencies like the National Institutes of Health, National Cancer Institute, and National Institute of Allergy and Infectious Diseases, Luminary Therapeutics has pursued multiple groundbreaking research projects. These grants have supported the development of innovative therapies such as a dual-action antigen-presenting CAR GD T-cell (DACART) therapy for solid tumors like colorectal and lung cancers, an allogeneic gamma/delta CAR T-cell therapy targeting epithelial ovarian carcinoma, and a BAFF ligand-based CAR T-cell approach for treating systemic lupus erythematosus and B-cell malignancies. The company leverages non-viral TCBuster transposon technology to generate these advanced cellular therapies, with a particular focus on creating allogeneic T-cell products that can potentially overcome current limitations in cancer and autoimmune disease treatments. Their research aims to enhance T-cell persistence, reduce antigen escape, and develop safer, more effective immunotherapeutic approaches across multiple disease domains.
SBA capabilities narrative
Biotechnology Therapeutic R&D
Quick answers
Is Luminary Therapeutics, Inc. registered in SAM.gov?
Yes. Luminary Therapeutics, Inc.'s SAM.gov registration is active through March 18, 2027.
What is Luminary Therapeutics, Inc.'s most recent federal award?
Luminary Therapeutics, Inc.'s most recent federal grant award is ΓΔ car t-cellular vaccine for solid cancers - solid tumors, such as colorectal cancer (CRC) and lung adenocarcinoma… (AY1AX000075), from National Institutes of Health, on January 27, 2025.
On GovTribe
See Luminary Therapeutics, Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors